RAF1 and neoplasm: Regorafenib is an orally available, small-molecule multikinase inhibitor that targets signaling pathways implicated in tumor angiogenesis(VEGF receptors 1–3 and TIE2), oncogenesis(KIT, RET, RAF1, and BRAF), and the tumor microenvironment (platelet-derived growth factor receptor and fibroblast growth factor receptor)[12].